IIT Study of M1-c6v1 Combined With SHR-1210 and Apatinib in Patients With HCC
Status:
Not yet recruiting
Trial end date:
2022-10-30
Target enrollment:
Participant gender:
Summary
This is a single arm and open-label phase I trial to evaluate the safety, tolerability and
efficacy of the oncolytic virus M1 （M1-c6v1）(iv 1×109 CCIC50, 1 dose per day, on day 1-5 each
28 day cycle) combined with anti-PD-1 antibody SHR-1201 (iv, 200 mg, once every two weeks)
and Apatinib (po. 250 mg qd ) in the patients with advanced/metastatic hepatocellular
carcinoma. 10 participants will be sequentially enrolled. The treatment duration is 12
months. All patients continue combination treatment until disease progression, unacceptable
toxicity, death, or discontinuation for any reason.